Jury investor panel member

Anne Marije van Harten | Investment Director | Apollo Health Ventures

Anne Marije is an Investment Director at Apollo Health Ventures, a leading venture capital firm focused on investing in innovative companies developing breakthrough therapies to extend healthy lifespan and target the biology of aging. At Apollo, Anne leads investments in companies addressing high unmet medical needs, with a strong biological rationale and relevance to aging biology.

Before joining Apollo, Anne began her investment career at Forbion, following academic training in both Europe and the United States. As a molecular cell biologist, her research focused on identifying novel therapeutic targets and molecules for disease-specific and personalized treatments.

About Apollo Health Ventures

Apollo Health Ventures is a transatlantic early-stage (Seed-Series A) venture capital firm that focuses on co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself. Our investment strategy includes active venture creation through partnerships with scientific experts and institutions, as well as investing in best-in-class companies at early stages. Apollo's portfolio features companies like Aeovian Pharmaceuticals, developing selective therapeutics for the mTORC1 pathway, and HAYA Therapeutics, focusing on long-noncoding RNA targets for fibrotic diseases.